Rithm Acquisition $230 million SPAC IPO
We advised Rithm Acquisition Corp., a SPAC, on its IPO and NYSE listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
BioVersys CHF 80 million IPO and concurrent private placement
We advised AMR Action Fund on its investment in BioVersys
SailPoint $1.4 billion IPO
The shares are listed on the Nasdaq Global Select Market
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Kioxia Holdings ¥120.4 billion IPO
The shares are listed on the Tokyo Stock Exchange
Venture Global $1.75 billion IPO
We advised Venture Global on its IPO and NYSE listing
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Rigaku Holdings ¥129.1 billion IPO
The shares are listed on the Tokyo Stock Exchange
Pony AI $413 million IPO
We advised Pony AI on its IPO, concurrent private placements and Nasdaq listing